TNFRSF1B Gene Variants in Clinicopathological Aspects and Prognosis of Patients with Cutaneous Melanoma

被引:1
作者
Carvalho, Bruna Fernandes [1 ]
Gomez, Gabriela Vilas Boas [1 ]
Carron, Juliana [1 ]
Macedo, Ligia Traldi [1 ,2 ]
Goncalves, Gisele Melo [3 ]
Vazquez, Vinicius de Lima [3 ]
Serrano, Sergio Vicente [4 ]
Lourenco, Gustavo Jacob [1 ]
Lima, Carmen Silvia Passos [1 ,2 ]
机构
[1] Univ Estadual Campinas, Sch Med Sci, Lab Canc Genet, BR-13083888 Campinas, SP, Brazil
[2] Univ Estadual Campinas, Sch Med Sci, Dept Anesthesiol Oncol & Radiol, BR-13083888 Campinas, SP, Brazil
[3] Barretos Canc Hosp, Melanoma & Sarcoma Surg Dept, BR-14784400 Barretos, SP, Brazil
[4] Barretos Canc Hosp, Dept Med Oncol, BR-14784400 Barretos, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
cutaneous melanoma; TNFRSF1B; single nucleotide variant; clinicopathological aspects; survival; TUMOR-NECROSIS-FACTOR; REGULATORY T-CELLS; TNF RECEPTOR 2; COLORECTAL-CANCER; LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; ARGININE POLYMORPHISM; PROSTATE-CANCER; MIR-96; PROMOTES; UP-REGULATION;
D O I
10.3390/ijms25052868
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Regulatory T lymphocytes play a critical role in immune regulation and are involved in the aberrant cell elimination by facilitating tumor necrosis factor connection to the TNFR2 receptor, encoded by the TNFRSF1B polymorphic gene. We aimed to examine the effects of single nucleotide variants TNFRSF1B c.587T>G, c.*188A>G, c.*215C>T, and c.*922C>T on the clinicopathological characteristics and survival of cutaneous melanoma (CM) patients. Patients were genotyped using RT-PCR. TNFRSF1B levels were measured using qPCR. Luciferase reporter assay evaluated the interaction of miR-96 and miR-1271 with the 3 ' -UTR of TNFRSF1B. The c.587TT genotype was more common in patients younger than 54 years old than in older patients. Patients with c.*922CT or TT, c.587TG or GG + c.*922CT or TT genotypes, as well as those with the haplotype TATT, presented a higher risk of tumor progression and death due to the disease effects. Individuals with the c.*922TT genotype had a higher TNFRSF1B expression than those with the CC genotype. miR-1271 had less efficient binding with the 3 ' -UTR of the T allele when compared with the C allele of the SNV c.*922C>T. Our findings, for the first time, demonstrate that TNFRSF1B c.587T>G and c.*922C>T variants can serve as independent prognostic factors in CM patients.
引用
收藏
页数:21
相关论文
共 137 条
[1]   A method and server for predicting damaging missense mutations [J].
Adzhubei, Ivan A. ;
Schmidt, Steffen ;
Peshkin, Leonid ;
Ramensky, Vasily E. ;
Gerasimova, Anna ;
Bork, Peer ;
Kondrashov, Alexey S. ;
Sunyaev, Shamil R. .
NATURE METHODS, 2010, 7 (04) :248-249
[2]  
American Joint Committee on Cancer (AJCC), 2010, AJCC Cancer Stating Manual, V7th ed.
[3]  
[Anonymous], 2020, Globocan Cancer Incidence and Mortality Worldwide Fast Stats
[4]  
Ansell Stephen M, 2013, Am Soc Clin Oncol Educ Book, DOI 10.1200/EdBook_AM.2013.33.e91
[5]   Tumour necrosis factor and cancer [J].
Balkwill, Frances .
NATURE REVIEWS CANCER, 2009, 9 (05) :361-371
[6]   MicroSNiPer: A Web Tool for Prediction of SNP Effects on Putative microRNA Targets [J].
Barenboim, Maxim ;
Zoltick, Brad J. ;
Guo, Yongjian ;
Weinberger, Daniel R. .
HUMAN MUTATION, 2010, 31 (11) :1223-1232
[7]   MicroRNAs: Target Recognition and Regulatory Functions [J].
Bartel, David P. .
CELL, 2009, 136 (02) :215-233
[8]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[9]   MicroRNA 603 acts as a tumor suppressor and inhibits triplenegative breast cancer tumorigenesis by targeting elongation factor 2 kinase [J].
Bayraktar, Recep ;
Pichler, Martin ;
Kanlikilicer, Pinar ;
Ivan, Cristina ;
Bayraktar, Emine ;
Kahraman, Nermin ;
Aslan, Burcu ;
Oguztuzun, Serpil ;
Ulasli, Mustafa ;
Arslan, Ahmet ;
Calin, George ;
Lopez-Berestein, Gabriel ;
Ozpolat, Bulent .
ONCOTARGET, 2017, 8 (07) :11641-11658
[10]   Internal quality control of PCR-based genotyping methods: practical experiences [J].
Bladbjerg, EM ;
Gram, K ;
Jespersen, J ;
de Maat, MPM .
VASCULAR PHARMACOLOGY, 2002, 39 (03) :127-129